Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 8 Feb 23 424B4 Prospectus supplement with pricing info
- 6 Feb 23 EFFECT Notice of effectiveness
- 3 Feb 23 S-1/A IPO registration (amended)
- 2 Feb 23 RW WD Withdrawal of registration withdrawal request
- 2 Feb 23 RW Registration withdrawal request
- 2 Feb 23 RW Registration withdrawal request
- 1 Feb 23 S-1/A IPO registration (amended)
-
26 Jan 23 S-1/A IPO registration (amended)
- 12 Jan 23 S-1 IPO registration
RSLS similar filings
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
ReShape Lifesciences, Inc.
San Clemente, California
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated April 8, 2022, except for the effect of the one-for-fifty reverse stock split discussed in Note 2 and Note 18, as to which the date is January 12, 2023, relating to the consolidated financial statements of ReShape Lifesciences, Inc., which is contained in that Prospectus.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Costa Mesa, California
January 26, 2023